Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hidekazu Shirota & Dennis M Klinman. (2014) Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Review of Vaccines 13:2, pages 299-312.
Read now
Read now
Xiaoyong Zhang, Anke Kraft, Ruth Broering, Joerg F Schlaak, Ulf Dittmer & Mengji Lu. (2012) Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opinion on Drug Discovery 7:7, pages 597-611.
Read now
Read now
Articles from other publishers (50)
Tingmei Zhao, Yulong Cai, Yujie Jiang, Xuemei He, Yuquan Wei, Yifan Yu & Xiaohe Tian. (2023) Vaccine adjuvants: mechanisms and platforms. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Naoto Tsujimura, Takayuki Ogino, Masayuki Hiraki, Taisei Kai, Hiroyuki Yamamoto, Haruka Hirose, Yuhki Yokoyama, Yuki Sekido, Tsuyoshi Hata, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Tsunekazu Mizushima, Yuichiro Doki, Hidetoshi Eguchi & Hirofumi Yamamoto. (2023) Super Carbonate Apatite-miR-497a-5p Complex Is a Promising Therapeutic Option against Inflammatory Bowel Disease. Pharmaceuticals 16:4, pages 618.
Crossref
Crossref
Lorenza Lia, Daniela Grima, Francesca Amici, Linda Manzi, Alessandro Monaci & Giuseppe La Torre. (2022) The Possible Protective Effect of Hepatitis B Vaccine against Lymphomas: A Systematic Review. Current Pharmaceutical Biotechnology 23:15, pages 1864-1872.
Crossref
Crossref
Li-na Hou, Feng-xue Wang, Ya-xin Wang, Hao Guo, Chun-yu Liu, Hong-zhe Zhao, Ming-hua Yu & Yong-jun Wen. (2022) Subunit vaccine based on glycoprotein B protects pattern animal guinea pigs from tissue damage caused by infectious bovine rhinotracheitis virus. Virus Research 320, pages 198899.
Crossref
Crossref
Jenny E. Hernandez-Davies, Emmanuel P. Dollinger, Egest J. Pone, Jiin Felgner, Li Liang, Shirin Strohmeier, Sharon Jan, Tyler J. Albin, Aarti Jain, Rie Nakajima, Algimantas Jasinskas, Florian Krammer, Aaron Esser-Kahn, Philip L. Felgner, Qing Nie & D. Huw Davies. (2022) Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants. Scientific Reports 12:1.
Crossref
Crossref
Alice Comberlato, Marianna M. Koga, Simone Nüssing, Ian A. Parish & Maartje M. C. Bastings. (2022) Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials. Nano Letters 22:6, pages 2506-2513.
Crossref
Crossref
Yan Yan, Yuanwang Qiu, Chantsalmaa Davgadorj & Chunfu Zheng. (2022) Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Crossref
Lei Wu, Wenhui Zhou, Lihua Lin, Anhong Chen, Jing Feng, Xiangmeng Qu, Hongbo Zhang & Jun Yue. (2022) Delivery of therapeutic oligonucleotides in nanoscale. Bioactive Materials 7, pages 292-323.
Crossref
Crossref
Simone E. Dekker, Ellen W. Green & Joseph Ahn. (2021) Treatment and Prevention of Acute Hepatitis B Virus. Clinics in Liver Disease 25:4, pages 711-724.
Crossref
Crossref
Conor Hennessy & Declan P. McKernan. (2021) Anti-Viral Pattern Recognition Receptors as Therapeutic Targets. Cells 10:9, pages 2258.
Crossref
Crossref
John W. Ward. 2021. Hepatitis B Virus and Liver Disease. Hepatitis B Virus and Liver Disease
169
203
.
Neslihan Kayraklioglu, Begum Horuluoglu & Dennis M. Klinman. 2021. DNA Vaccines. DNA Vaccines
51
85
.
Seyed Mohammad Ali Hashemi, Fatemeh Hashemzadeh, Helen Bahrampour, Fatemeh Nekoei, Negar Joharinia & Jamal Sarvari. (2020) The evaluation anti-HBsAb titer among university students in Shiraz, 2019. Iranian Journal of Medical Microbiology 14:4, pages 297-306.
Crossref
Crossref
Daniel Shouval. 2020. Clinical Dilemmas in Viral Liver Disease. Clinical Dilemmas in Viral Liver Disease
169
174
.
Declan P. McKernan. 2020. Inflammatory Disorders, Part A. Inflammatory Disorders, Part A
65
109
.
Alice Comberlato, Kaltrina Paloja & Maartje M. C. Bastings. (2019) Nucleic acids presenting polymer nanomaterials as vaccine adjuvants. Journal of Materials Chemistry B 7:41, pages 6321-6346.
Crossref
Crossref
Kyle M. Garland, Sema Sevimli, Kameron V. Kilchrist, Craig L. Duvall, Rebecca S. Cook & John T. Wilson. (2019) Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles. Cellular and Molecular Bioengineering 12:5, pages 429-442.
Crossref
Crossref
Zhiyong Ma, Ejuan Zhang, Shicheng Gao, Yong Xiong & Mengji Lu. (2019) Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Frontiers in Immunology 10.
Crossref
Crossref
Anusha Vittal & Marc G. Ghany. (2019) WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV. Clinics in Liver Disease 23:3, pages 417-432.
Crossref
Crossref
Kevin Brown, Montserrat Puig, Lydia Haile, Derek Ireland, John Martucci & Daniela Verthelyi. 2018. Oligonucleotide-Based Drugs and Therapeutics. Oligonucleotide-Based Drugs and Therapeutics
411
444
.
Aleksei Suslov, Stefan Wieland & Stephan Menne. (2018) Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Current Opinion in Virology 30, pages 9-17.
Crossref
Crossref
Zhiyong Ma, Qian Cao, Yong Xiong, Ejuan Zhang & Mengji Lu. (2018) Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. Vaccines 6:1, pages 6.
Crossref
Crossref
Pierre Van Damme, John W. Ward, Daniel Shouval & Alessandro Zanetti. 2018. Plotkin's Vaccines. Plotkin's Vaccines
342
374.e17
.
J Wolf. 2018. Comprehensive Toxicology. Comprehensive Toxicology
852
872
.
John W. Ward & Pierre Van Damme. 2018. Hepatitis B Virus and Liver Disease. Hepatitis B Virus and Liver Disease
91
117
.
Xueyan Cao, Xueguang Lu, Dali Wang, Fei Jia, Xuyu Tan, Michelle Corley, Xiaoying Chen & Ke Zhang. (2017) Modulating the Cellular Immune Response of Oligonucleotides by Brush Polymer‐Assisted Compaction. Small 13:43, pages 1701432.
Crossref
Crossref
Margaret Stanley. (2017) Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philosophical Transactions of the Royal Society B: Biological Sciences 372:1732, pages 20160268.
Crossref
Crossref
Mihaela-Olivia Dobrica, Catalin Lazar, Lisa Paruch, Hanne Skomedal, Hege Steen, Sissel Haugslien, Catalin Tucureanu, Iuliana Caras, Adrian Onu, Sonya Ciulean, Alexandru Branzan, Jihong Liu Clarke, Crina Stavaru & Norica Branza-Nichita. (2017) A novel chimeric Hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein. Antiviral Research 144, pages 256-265.
Crossref
Crossref
K.L. Wilson, S.D. Xiang & M. Plebanski. 2017. Micro and Nanotechnology in Vaccine Development. Micro and Nanotechnology in Vaccine Development
99
125
.
H. Shirota & D.M. Klinman. 2017. Immunopotentiators in Modern Vaccines. Immunopotentiators in Modern Vaccines
163
198
.
Werner Dammermann, Frank Bentzien, Eva-Maria Stiel, Claudia Kühne, Sebastian Ullrich, Julian Schulze zur Wiesch & Stefan Lüth. (2015) Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients. Journal of Translational Medicine 13:1.
Crossref
Crossref
Ejuan Zhang, Anna Kosinska, Mengji Lu, Huimin Yan & Michael Roggendorf. (2015) Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA. Antiviral Research 123, pages 193-203.
Crossref
Crossref
Dimpy P. ShahCarolyn Z. GrimesAnh T. NguyenDejian LaiLu-Yu Hwang. (2015) Long-Term Effectiveness of Accelerated Hepatitis B Vaccination Schedule in Drug Users. American Journal of Public Health 105:6, pages e36-e43.
Crossref
Crossref
Zhiyong Ma, Ejuan Zhang, Dongliang Yang & Mengji Lu. (2014) Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cellular & Molecular Immunology 12:3, pages 273-282.
Crossref
Crossref
Aleksandar F. Radovic-Moreno, Natalia Chernyak, Christopher C. Mader, Subbarao Nallagatla, Richard S. Kang, Liangliang Hao, David A. Walker, Tiffany L. Halo, Timothy J. Merkel, Clayton H. Rische, Sagar Anantatmula, Merideth Burkhart, Chad A. Mirkin & Sergei M. Gryaznov. (2015) Immunomodulatory spherical nucleic acids. Proceedings of the National Academy of Sciences 112:13, pages 3892-3897.
Crossref
Crossref
Hans-Heinrich Hoffmann, William M. Schneider & Charles M. Rice. (2015) Interferons and viruses: an evolutionary arms race of molecular interactions. Trends in Immunology 36:3, pages 124-138.
Crossref
Crossref
Geert Leroux-Roels. (2014) Old and new adjuvants for hepatitis B vaccines. Medical Microbiology and Immunology 204:1, pages 69-78.
Crossref
Crossref
Ejuan Zhang & Mengji Lu. (2014) Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Medical Microbiology and Immunology 204:1, pages 11-20.
Crossref
Crossref
Saqib Walayat. (2015) Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World Journal of Hepatology 7:24, pages 2503.
Crossref
Crossref
NIRIANNE MARIE Q. PALACPAC, TAKAHIRO TOUGAN & TOSHIHIRO HORII. (2015) Preclinical Studies on a New Vaccine Formulation of BK-SE36, a Malaria Vaccine Candidate. Juntendo Medical Journal 61:4, pages 360-369.
Crossref
Crossref
David Gordon, Peter Kelley, Susanne Heinzel, Peter Cooper & Nikolai Petrovsky. (2014) Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study. Vaccine 32:48, pages 6469-6477.
Crossref
Crossref
Anne Endmann, Katharina Klünder, Kerstin Kapp, Oliver Riede, Detlef Oswald, Eduard G. Talman, Matthias Schroff, Christiane Kleuss, Marcel H. J. Ruiters & Christiane Juhls. (2014) Cationic Lipid-Formulated DNA Vaccine against Hepatitis B Virus: Immunogenicity of MIDGE-Th1 Vectors Encoding Small and Large Surface Antigen in Comparison to a Licensed Protein Vaccine. PLoS ONE 9:7, pages e101715.
Crossref
Crossref
Sandra N. Lester & Kui Li. (2014) Toll-Like Receptors in Antiviral Innate Immunity. Journal of Molecular Biology 426:6, pages 1246-1264.
Crossref
Crossref
Dan Yang, Longchao Liu, Danming Zhu, Hua Peng, Lishan Su, Yang-Xin Fu & Liguo Zhang. (2013) A mouse model for HBV immunotolerance and immunotherapy. Cellular & Molecular Immunology 11:1, pages 71-78.
Crossref
Crossref
Werner Dammermann, Lisa Wollenberg, Frank Bentzien, Ansgar Lohse & Stefan Lüth. (2013) Toll like receptor 2 agonists lipoteichoic acid and peptidoglycan are able to enhance antigen specific IFNγ release in whole blood during recall antigen responses. Journal of Immunological Methods 396:1-2, pages 107-115.
Crossref
Crossref
Peter Pushko, Paul Pumpens & Elmars Grens. (2013) Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures. Intervirology 56:3, pages 141-165.
Crossref
Crossref
Pierre Van Damme, John Ward, Daniel Shouval, Steven Wiersma & Alessandro Zanetti. 2013. Vaccines. Vaccines
205
234
.
Greet Hendrickx, Alex Vorsters & Pierre Van Damme. (2012) Advances in hepatitis immunization (A, B, E). Current Opinion in Infectious Diseases 25:5, pages 578-583.
Crossref
Crossref
N. J. Horscroft, D. C. Pryde & H. Bright. (2012) Antiviral applications of Toll-like receptor agonists. Journal of Antimicrobial Chemotherapy 67:4, pages 789-801.
Crossref
Crossref
Mark A. Tomai & John P. Vasilakos. 2012. Innovation in Vaccinology. Innovation in Vaccinology
205
228
.